Artelo Biosciences files $6.5M at-the-market offering prospectus

Artelo Biosciences (NASDAQ: ARTL) filed a prospectus supplement for an at-the-market offering program to sell up to $6.53 million of common stock through H.C. Wainwright & Co. as exclusive sales agent.

The biotechnology company entered into an At the Market Offering Agreement with H.C. Wainwright dated May 26, 2026. Under the arrangement, shares will be sold at market prices through existing trading markets when and if the company chooses to make sales.

H.C. Wainwright will receive a 3% commission on the gross sales price of shares sold and is not required to sell any specific number or dollar amount of securities. The sales agent will use commercially reasonable efforts consistent with normal trading practices to sell shares on behalf of Artelo.

The company's common stock has a par value of $0.001 per share. Sales under the program are considered at-the-market offerings as defined under Rule 415(a)(4) of the Securities Act of 1933.

Artelo has agreed to provide indemnification and contribution to H.C. Wainwright against certain civil liabilities, including those under the Securities Act. No funds will be held in escrow or trust arrangements under the agreement.

If the companies agree on distribution methods other than market-price sales through existing trading markets, Artelo will file an additional prospectus supplement with required offering information.

You May Also Be Interested In

• Gyre Therapeutics (GYRE) files for 30.22M share offering by selling stockholders
• Nokia unveils agentic AI tools for telecom network automation
• Uxin reports Q1 2026 sales up 119%, eyes 100+ unit target